Company Valuation: Founding Construction Development Corp.

Data adjusted to current consolidation scope
Fiscal Period: December 2020 2021 2022 2023 2024 2025
Market Cap 1 4,592 5,448 5,006 6,903 5,762 4,136
Change - 18.63% -8.12% 37.89% -16.53% -28.22%
Enterprise Value (EV) 1 9,883 8,471 4,526 5,449 4,202 3,193
Change - -14.28% -46.58% 20.41% -22.89% -24.01%
P/E 18.9x 5.13x 4.94x 7.78x 13.6x 26.1x
PBR 0.62x 0.65x 0.55x 0.72x 0.59x 0.43x
PEG - 0x -1.08x -0.6x -0.3x -0.4x
Capitalization / Revenue 1.2x 1.44x 1.04x 1.83x 2.58x 3.55x
EV / Revenue 2.58x 2.25x 0.94x 1.45x 1.88x 2.74x
EV / EBITDA 24.8x 9.67x 4.15x 5.13x 7.83x 14.7x
EV / EBIT 31.5x 10.7x 4.38x 5.44x 8.79x 19.5x
EV / FCF 12.7x 6.29x 1.33x 3.19x 16.4x -2.7x
FCF Yield 7.87% 15.9% 75.4% 31.3% 6.09% -37%
Dividend per Share 2 0.6 1 1.2 1.2 1 0.6
Rate of return 3.73% 5.24% 6.84% 4.96% 4.95% 4.14%
EPS 2 0.85 3.72 3.55 3.11 1.48 0.5555
Distribution rate 70.6% 26.9% 33.8% 38.6% 67.6% 108%
Net sales 1 3,835 3,772 4,816 3,764 2,236 1,165
EBITDA 1 398.7 876.3 1,091 1,062 536.4 217.7
EBIT 1 313.4 794.1 1,033 1,002 478.2 163.6
Net income 1 242.8 1,062 1,015 889.5 423 158.5
Net Debt 1 5,290 3,023 -480.5 -1,454 -1,560 -943.2
Reference price 2 16.10 19.10 17.55 24.20 20.20 14.50
Nbr of stocks (in thousands) 285,245 285,245 285,245 285,245 285,245 285,245
Announcement Date 3/17/21 3/17/22 3/14/23 3/14/24 3/11/25 3/16/26
1TWD in Million2TWD
Estimates

P/E (N) EV / Sales (N) EV / EBITDA (N) Dividend Yield (N) Capi.($)
- - - - 125M
14.67x4.69x12.59x3.45% 41.77B
21.37x4.33x17.75x1.17% 31.57B
5.96x0.7x1.45x8.38% 28.73B
8.16x1.43x7.19x4.37% 29.38B
14.29x3.1x14.88x2.46% 25.55B
15.65x1x6.59x2.38% 21.73B
15.47x6.9x18.52x1.38% 21.85B
8.59x2.18x6.97x4.11% 19.88B
7.69x1.7x5.49x2.89% 17.25B
Average 12.43x 2.89x 10.16x 3.4% 23.78B
Weighted average by Cap. 12.81x 3.03x 10.52x 3.48%

Y-o-Y evolution of P/E

Historical PBR trend

Evolution Enterprise Value / Sales

Change in Enterprise Value/EBITDA

  1. Stock Market
  2. Stocks
  3. 5533 Stock
  4. Valuation Founding Construction Development Corp.